Showing results (1-10 of 27) with videos related to
Sort By:
Pageof 3
Current Opinion in Urology|December 20, 2002
Aetiology and pathogenesis of benign prostatic hyperplasiaColby L EatonCancer Treatment Reviews|June 6, 2003
Pathophysiology of bone metastases from prostate cancer and the role of bisphosphonates in treatmentColby L Eaton, R E ColemanCancer Research|March 26, 2002
Osteoprotegerin (OPG) is a survival factor for human prostate cancer cellsIngunn Holen, Peter I Croucher, Freddie C Hamdy, et al.The Prostate|March 26, 2004
Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancerColby L Eaton, Jason M Wells, Ingunn Holen, et al.Growth Factors (Chur, Switzerland)|March 27, 2007
Opposing actions of TGFbeta1 and FGF2 on growth, differentiation and extracellular matrix accumulation in prostatic stromal cellsNeil A Cross, Sheilagh V Reid, Amanda J Harvey, et al.Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|September 10, 2004
Human bone marrow stromal cells protect prostate cancer cells from TRAIL-induced apoptosisRachel Nyambo, Neil Cross, Jenny Lippitt, et al.Endocrine-Related Cancer|July 24, 2014
Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bonePenelope D Ottewell, Ning Wang, Joshua Meek, et al.Biotechnology and Applied Biochemistry|October 6, 2017
The BMP antagonist Noggin is produced by osteoblasts in response to the presence of prostate cancer cellsHuda F AlShaibi, Farid Ahmed, Clive Buckle, et al.International Journal of Cancer|January 22, 2015
OPG-Fc inhibits ovariectomy-induced growth of disseminated breast cancer cells in bonePenelope D Ottewell, Ning Wang, Hannah K Brown, et al.European Urology|February 26, 2003
The survival effect of prolactin on PC3 prostate cancer cellsAlain Ruffion, Kaltoom A Al-Sakkaf, Barry L Brown, et al.Pageof 3